The discovery of sofosbuvir: A revolution for therapy of chronic hepatitis C

Expert Opinion on Drug Discovery

Volumn 10, Issue 12, 2015, Pages 1363-1377

  Gentile, Ivan ^a   Maraolo, Alberto Enrico ^a   Buonomo, Antonio Riccardo ^a   Zappulo, Emanuela ^a   Borgia, Guglielmo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cirrhosis; GS 7977; hepatitis C virus; IFN free regimens; PSI 7977; ribavirin; sustained virological response

Indexed keywords

ANTIRETROVIRUS AGENT; BOCEPREVIR; DACLATASVIR; GS 331007; IMMUNOSUPPRESSIVE AGENT; LEDIPASVIR; METHADONE; NONSTRUCTURAL PROTEIN 5B; ORAL CONTRACEPTIVE AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; RIFAMPICIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

ANEMIA; ANTIVIRAL ACTIVITY; CELL ACTIVATION; CHEMICAL ANALYSIS; CHRONIC HEPATITIS C; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INSOMNIA; LIFE CYCLE; LIVER DISEASE; LIVER TRANSPLANTATION; MANAGED CARE; MEDICAL HISTORY; MIXED INFECTION; NONHUMAN; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VIRUS RESISTANCE; ANIMAL; COMBINATION DRUG THERAPY; DRUG DESIGN; DRUG DEVELOPMENT; HEPATITIS C, CHRONIC; PRECLINICAL STUDY; PROCEDURES; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; SOFOSBUVIR;

EID: 84948587975     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1094051     Document Type: Review

References (127)

1. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015; 385: 1124-35
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 1: 74-81
3. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-62
4. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61 (1 Suppl): 30
5. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38
6. Gentile I, Coppola N, Pasquale G, et al. A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C. Hepat Mon 2013; 13: e8352
7. Gentile I, Scarano F, Celotti A, et al., Low Vitamin D. Levels Are Associated with the Presence of Serum Cryoglobulins in Patients with Chronic HCV Infection. In Vivo 2015; 29: 399-404
8. Fusco F, DAnzeo G, Rossi A, et al. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. Expert Opin Pharmacother 2013; 14: 2533-44
9. WHO. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-71
10. Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol 2015; 7: 1377-89
11. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-27
12. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87
13. Gray RR, Salemi M, Klenerman P, et al. A new evolutionary model for hepatitis C virus chronic infection. PLoS Pathog 2012; 8: 3
14. Thimme R, Binder M, Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev 2012; 36: 663-83
15. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-6
16. Shulla A, Randall G. Hepatitis C virus-host interactions, replication, and viral assembly. Curr Opin Virol 2012; 2: 725-32
17. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013; 11: 482-96
18. Gentile I, Borgia G. A pill a day keeps HCV away. Lancet Infect Dis 2015; 15: 616-17
19. Gentile I, Buonomo AR, Zappulo E, et al. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world Expert Rev Anti Infect Ther 2014; 12: 763-73
20. Gentile I, Coppola N, Buonomo AR, et al. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs 2014; 23: 1211-23
21. Gentile I, Buonomo AR, Borgia F, et al. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs 2014; 23: 561-71
22. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62
23. Kohli A, Shaffer A, Sherman A, et al. Treatment of hepatitis C: a systematic review. Jama 2014; 312: 631-40
24. EASL. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 21: 00208-1
25. Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19: 2793-8
26. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama 2012; 308: 2584-93
27. Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010; 52: 778
28. Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 478-87
29. Gentile I, Viola C, Reynaud L, et al. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. J Interferon Cytokine Res 2005; 25: 283-5
30. Tosone G, Borgia G, Gentile I, et al. A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided Acta Diabetol 2007; 44: 167-9
31. Rosina F, Tosti ME, Borghesio E, et al. Pegylated interferon alpha plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency. Dig Liver Dis 2014; 46: 826-32
32. Chung RT, Gale M Jr, Polyak SJ, et al. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology 2008; 47: 306-20
33. Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of "perfectovir". Clin Infect Dis 2015; 60: 1829-36
34. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17
35. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16
36. Gentile I, Carleo MA, Borgia F, et al. The efficacy and safety of telaprevir-a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010; 19: 151-9
37. Bruno S, Bollani S, Zignego AL, et al. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. J Viral Hepat 2015; 22: 469-80
38. Shahid I, WH AL, Hafeez MH, et al. Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies. Crit Rev Microbiol 2014; 6: 1-13
39. Bartenschlager R, Penin F, Lohmann V, et al. Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011; 19: 95-103
40. Gentile I, Borgia F, Buonomo AR, et al. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013; 20: 3733-42
41. Gerold G, Pietschmann T. The HCV life cycle: in vitro tissue culture systems and therapeutic targets. Dig Dis 2014; 32: 525-37
42. Asselah T, Marcellin P. New direct-acting antivirals combination for the treatment of chronic hepatitis C. Liver Int 2011; 1: 68-77
43. Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. Embo J 1996; 15: 12-22
44. Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-13
45. Soriano V, Vispo E, de Mendoza C, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother 2013; 14: 1161-70
46. Ago H, Adachi T, Yoshida A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 1999; 7: 1417-26
47. Bressanelli S, Tomei L, Roussel A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 1999; 96: 13034-9
48. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004; 85: 3173-88
49. Delang L, Neyts J, Vliegen I, et al. Hepatitis C virus-specific directly acting antiviral drugs. Curr Top Microbiol Immunol 2013; 369: 289-320
50. Madela K, McGuigan C. Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs. Future Med Chem 2012; 4: 625-50
51. Keating GM, Vaidya A. Sofosbuvir: first global approval. Drugs 2014; 74: 273-82
52. Gounder C. A better treatment for hepatitis C. The New Yorker, December 2013. Available from: www.newyorker.com/tech/elements/a-better-treatment-for-hepatitis-c. [Last accessed 31 August 2013]
53. Pharmasset Ltd. Modified fluorinated nucleoside analogues. WO2005003147A2; 2005
54. Wang P, Chun BK, Rachakonda S, et al. An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase. J Org Chem 2009; 74: 6819-24
55. Peifer M, Berger R, Shurtleff VW, et al. A general and enantioselective approach to pentoses: a rapid synthesis of PSI-6130, the nucleoside core of sofosbuvir. J Am Chem Soc 2014; 136: 5900-3
56. Sofia MJ, Bao D, Chang W, et al. Discovery of a beta-d-2-deoxy-2-alpha-fluoro-2-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010; 53: 7202-18
57. Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 2010; 285: 34337-47
58. Kirby BJ, Symonds WT, Kearney BP, et al. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Clin Pharmacokinet 2015; 31: 31
59. Herbst DA Jr, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013; 22: 527-36
60. Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-20
61. Rodriguez-Torres M. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Rev Anti Infect Ther 2013; 11: 1269-79
62. Babusis D, Curry MP, Denning J, et al. Translational Studies to understand the mechanism of liver delivery by sofosbuvir. Presented at 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; Washington DC, USA, 2014
63. Lam AM, Murakami E, Espiritu C, et al. PSI-7851, a pronucleotide of beta-D-2-deoxy-2-fluoro-2-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother 2010; 54: 3187-96
64. Guedj J, Pang PS, Denning J, et al. Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antivir Ther 2014; 19: 211-20
65. Hebner CM, Lee YJ, Han B, et al. In vitro pangenotypic and combination activity of sofosbuvir in stable replicon cell lines. Presented at 63th Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA, USA, 2012
66. Cholongitas E, Papatheodoridis GV. Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol 2014; 27: 331-7
67. Lawitz E, Rodriguez-Torres M, Cornpropst MT, et al. The effect of hepatic impairment in the pharmacokinetics and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for several days. Presented at 47th Annual Meeting of the European Association for the Study of the Liver; Barcelona, Spain; 2012
68. Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of GS-7977. Presented at 47th Annual Meeting of the European Association for the Study of the Liver; Barcelona, Spain; 2012
69. Gane E, Robson RA, Bonacini M, et al. Safety, antiviral efficacy, and pharmacokinetics of sofosbuvir in patients with severe renal impairment. Presented at 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA; 2014
70. Denning J, Cornpropst M, Flach SD, et al. Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects. Antimicrob Agents Chemother 2013; 57: 1201-8
71. Lawitz E, Rodriguez-Torres M, Denning JM, et al. Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection. Antimicrob Agents Chemother 2013; 57: 1209-17
72. Noell BC, Besur SV, deLemos AS. Changing the face of hepatitis C management-the design and development of sofosbuvir. Drug Des Devel Ther 2015; 9: 2367-74
73. Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol 2013; 58: 663-8
74. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401-8
75. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-7
76. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44
77. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. Jama 2013; 310: 804-11
78. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87
79. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77
80. Mangia A, Piazzolla V. Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies. Dig Liver Dis 2014; 15: 31
81. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001
82. Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012; 56: 3359-68
83. Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 2014; 59: 1666-74
84. Donaldson EF, Harrington PR, ORear JJ, et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015; 61: 56-65
85. Gordon S, Contai S, Tournee W. Integrated safety analysis of sofosbuvir-based HCV treatment regimens from phase III studies. J Hepatol 2014; 60: S361-522
86. Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gastroenterol 2014; 7: 131-40
87. Kayali Z, Schmidt WN. Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. Pharmgenomics Pers Med 2014; 7: 387-98
88. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65
89. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98
90. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93
91. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88
92. Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology 2015; 62: 25-30
93. Kapoor R, Kohli A, Sidharthan S. All-oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. Hepatology 2014; 60: 321
94. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21
95. Coppola N, Martini S, Pisaturo M, et al. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World J Virol 2015; 4: 1-12
96. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-13
97. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. Jama 2014; 312: 353-61
98. Shafran SD. HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: Its Time to End Segregation and Integrate HIV Patients Into HCV Trials. Clin Infect Dis 2015; 9. [Epub ahead of print]
99. Naggie S, Cooper C, Saag M, et al. Ledipasvir/Sofosbuvir for 12 Weeks in Patients Coinfected With HCV and HIV. Presented at Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, WA, USA; 2015
100. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-7
101. EASL. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64
102. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-7
103. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96
104. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-17
105. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease. Gastroenterology 2015; 15: 00682-4
106. Recommendations for Testing, Managing, and Treating Hepatitis C. Guidelines from AASLD/IDSA/IAS-USA. Available from: www.HCVguidelines.org. [Last accessed 31 August, 2015]
107. Poordad F, Sievert W, Mollison L, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with hcv genotype 1 infection. JAMA 2015; 313: 1728-35
108. In brief: severe bradycardia with sofosbuvir and amiodarone. Med Lett Drugs Ther 2015; 57: 58
109. Jensen DM, OLeary JG, Pockros PJ. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: realworld experience in a diverse, longitudinal observational cohort act). Hepatology 2014; 60: 219
110. Dieterich D, Bacon BR, Flamm SL. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014; 60: 220
111. De Lemos AS, Chung RT. Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med 2014; 20: 315-21
112. Pawlotsky JM, Feld JJ, Zeuzem S, et al. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 2015; 62 (1 Suppl): 006
113. Asselah T, Estrabaud E, Bieche I, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010; 30: 1259-69
114. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9
115. Coppola N, Marrone A, Pisaturo M, et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014; 33: 559-67
116. Gentile I, Viola C, Paesano L, et al. Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. J Clin Apher 2009; 24: 190-6
117. Degasperi E, Aghemo A. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med 2014; 6: 25-33
118. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146: 1176-92
119. McCarthy M. New drug for hepatitis C contributes to 13% rise in spending on prescription drugs in US. BMJ 2015; 350: 2055
120. Pfeil AM, Reich O, Guerra IM, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS ONE 2015; 10: e0126984
121. Reiberger T. Chronic hepatitis C: treat everyone now or stratify by disease Minerva Gastroenterol Dietol 2015; 61: 11-19
122. Stirnimann G. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother 2014; 15: 2609-22
123. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-23
124. Foster GR, Pianko S, Brown A, et al. Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-alfa in Patients With HCV Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and HCV Genotype 2 Infection. Gastroenterology 2015; Epub ahead of print
125. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127-35
126. Esmat GE, Shiha G, Omar RF, et al. Sofosbuvir plus ribavirin in the treatment of Egyptian patients with chronic genotype 4 HCV infection. Presented at 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston (MA), USA; 2014
127. Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks with HCV genotype 3 or 6 infection. Presented at 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA, USA; 2014